{"SPADE_UN_28473": {"Sequence Information": {"Peptide Name": "Reduced Gomesin", "Sequence": "XCRRLCYKQRCVTYCRGR", "Sequence Length": 18, "Biological Activity": ["Anti-Gram+", "Anti-Gram-", "Anticancer", "Antifungal", "Anti-Mammalian Cell"], "Binding Target": "1. Lipid Bilayer", "Source": "", "Gene": "", "PDB ID": "", "UniProt Entry": [{"uniprotId": "P82358", "uniprotUrl": "http://www.uniprot.org/uniprot/P82358", "description": "The amino acid sequence of the current peptide coincides with the part of the UniProt entry that represents a peptide precursor."}], "Literature": [{"Title": "Structure-activity relationship studies of gomesin: importance of the disulfide bridges for conformation, bioactivities, and serum stability.", "Pubmed ID": "16235231", "Reference": "Biochemistry. 2006;84:205-218", "Author": "Fázio MA, Oliveira VX Jr, Bulet P, Miranda MT, Daffre S, Miranda A", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/16235231"}, {"Title": "Redesigned Spider Peptide with Improved Antimicrobial and Anticancer Properties.", "Pubmed ID": "28741926", "Reference": "ACS Chem Biol. 2017;:", "Author": "Troeira Henriques S, Lawrence N, Chaousis S, Ravipati AS, Cheneval O, Benfield AH, Elliott AG, Kavanagh AM, Cooper MA, Chan LY, Huang YH, Craik DJ", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/28741926"}], "SPADE ID": "SPADE_UN_28473", "Similar Sequences": [{"SPADE_ID": "SPADE_N_03752", "Similarity": 1.0, "Sequence": "CRRLCYKQRCVTYCRGR"}, {"SPADE_ID": "SPADE_N_03753", "Similarity": 1.0, "Sequence": "CRRLCYKQRCVTYCRG"}, {"SPADE_ID": "SPADE_N_05695", "Similarity": 1.0, "Sequence": "QCRRLCYKQRCVTYCRGR"}], "Hemolytic Activity": "Human foreskin fibroblasts (HFF):CC50=58.2±3.0 µM,Human erythrocytes:30.7±8.1% Hemolysis=64 µM", "Target Organism": "Staphylococcus aureus ATCC 6538(MIC=>81.92µM),Escherichia coli SBS 363(MIC=10.24-20.5µM),Candida albicans MDM8(MIC=2.56-5.12µM),Escherichia coli ATCC 25922(MIC=49.9±16.6µM),Staphylococcus aureus ATCC 25923(MIC=32µM),Human gastric adenocarcinoma CRL-1739(50% Cell death=>64µM),Human skin melanoma MM96L(50% Cell death=8.6±0.8µM),Human cervical carcinoma HeLa(50% Cell death=>64µM),Human myelogenous leukemia K562(50% Cell death=2.7±0.2µM)"}}}